Harwood Feffer LLP Announces Investigation of MiMedx Group, Inc.
NEW YORK, Sept. 5, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG), concerning whether the board has breached its fiduciary duties to shareholders.
On September 4, 2013, MiMedx disclosed that it had received a letter from U.S. Food and Drug Administration ("FDA") alleging that the Company manufactures and markets pharmaceutical drugs in violation of the Public Health Service Act.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own MiMedx shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP
More by this Source
Harwood Feffer LLP Announces Investigation of Imperva, Inc.
Apr 15, 2014, 15:29 ET
Harwood Feffer LLP Announces Investigation of InterCloud Systems, Inc.
Apr 11, 2014, 21:00 ET
Harwood Feffer LLP Announces Investigation of GrowLife, Inc.
Apr 11, 2014, 20:45 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.